肿瘤免疫治疗相关动脉粥样硬化的研究进展  

Atherosclerosis Associated with Cancer Immune Therapy

作　　者：孙睿 王阿曼[1] SUN Rui;WANG Aman(Department of Oncology,The First Affiliated Hospital of Dalian Medical University,Dalian 116000,Liaoning,China)

机构地区：[1]大连医科大学附属第一医院肿瘤内科,辽宁大连116000

出　　处：《心血管病学进展》2023年第7期585-588,597,共5页Advances in Cardiovascular Diseases

基　　金：国家自然科学基金青年基金(81502024)。

摘　　要：免疫检查点抑制剂(ICI)的应用改善了多种肿瘤的疗效和预后,然而其特有的免疫相关不良事件,尤其是心脏毒性受到关注。最近的研究发现ICI治疗可能通过促进动脉慢性炎症导致或加重动脉粥样硬化,机制尚不十分明确。现重点对ICI相关动脉粥样硬化的流行病学、病理生理机制、影像学特征和药物治疗方面的进展进行综述,旨在提高临床医生对该心血管免疫相关不良事件的认识和诊疗水平。The application of immune checkpoint inhibitors(ICI)has improved the efficacy and prognosis of a variety of tumors.However,its unique immune-related adverse events,especially cardiotoxicity,have attracted much attention.Recent studies have found that ICI therapy may cause or aggravate atherosclerosis by promoting chronic inflammation of the arteries,but the mechanism is not fully understood.This review focuses on the epidemiology,pathophysiological mechanisms,imaging features and drug therapy of ICI-related atherosclerosis,with the aim of improving the understanding and diagnosis level of cardiovascular immune-related adverse events among clinicians.

关 键 词：动脉粥样硬化 免疫检查点抑制剂 免疫相关不良事件 心血管毒性 

分 类 号：R730.51[医药卫生—肿瘤]